Related Experiment Videos
[Probenecid affects liver metabolism]
A Bammel1, H Mönig, K H Zurborn
1I. Medizinische Klinik, Christian-Albrechts-Universität, Kiel.
Schweizerische Medizinische Wochenschrift
|December 16, 1989
Summary
Probenecid significantly alters phenprocoumon (PPC) pharmacokinetics by decreasing excretion and shortening half-life. It also impacts protein-C-antigen levels and affects antipyrine and cortisol metabolism, suggesting enzyme-inducing properties.
Area of Science:
- Pharmacology
- Drug Metabolism
- Clinical Pharmacology
Background:
- Phenprocoumon (PPC) is a vitamin K antagonist with a narrow therapeutic index.
- Understanding drug interactions is crucial for safe and effective anticoagulation therapy.
Purpose of the Study:
- To investigate the pharmacokinetic interactions between probenecid and phenprocoumon (PPC) in healthy volunteers.
- To assess the effect of probenecid on vitamin K-dependent protein-C-antigen levels.
- To evaluate probenecid's impact on the pharmacokinetics of antipyrine and 6 beta-hydroxycortisol.
Main Methods:
- 14 healthy volunteers received single oral or intravenous doses of PPC.
- Probenecid was administered for 7 days to assess its effects.
- Pharmacokinetic parameters of PPC, antipyrine, and 6 beta-hydroxycortisol were measured.
- Plasma protein-C-antigen concentrations were monitored.
Main Results:
- Probenecid decreased urinary excretion of PPC and PPC-glucuronide by 75%.
- Probenecid significantly shortened the plasma half-life of PPC by approximately 35%.
- Probenecid increased plasma protein-C-antigen concentrations and diminished antipyrine half-life, with increased 6 beta-hydroxycortisol excretion.
Conclusions:
- Probenecid exhibits enzyme-inducing properties, potentially shortening phenprocoumon's plasma half-life.
- Probenecid's influence on protein-C-antigen suggests broader effects on hepatic metabolism.
- These findings highlight potential drug interactions relevant to clinical practice.